FDA
-
-
-
-
-
-
-
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
-
-
-
-
-
-
-
Precigen reports 200 patients enrolled for FDA-approved RRP therapy
-
-
-
-
-
-
-
Precigen receives FDA approval for PAPZIMEOS to treat rare respiratory disease
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Precigen Inc. (PGEN)
-
-
-
-
-
-
-
Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates
-
-
-
-
-
-
-
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
-
-
-
-
-
-
-
Precigen (PGEN) Granted FDA Orphan Drug Designation for PRGN-2012
-
328,268 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

